Summary
Rockwell Medical, Inc., together with its subsidiaries, operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis in the United States and internationally. The company offers Triferic Dialysate and Triferic AVNU, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including blood tubing, fistula needles, dialyzers, drugs, specialized component kits, dressings, cleaning agents, filtration salts, and other supplies used by hemodialysis providers. The company's dialysis concentrate products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream. It is also developing other therapeutic product candidates for the treatment of hospitalized patients with acute heart failure; and home infusion therapy that allows patients to receive intravenous medications at home. Its target customers include medium and small sized dialysis chains and independent dialysis centers. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.
History
Rockwell Medical was founded in 1996 and headquartered in Wixom, Michigan. It began commercial manufacturing of dialysis concentrates at Michigan facility in 1997. In 2005, Rockwell acquired rights to Triferic from the University of Michigan. In 2017, the company opened drug manufacturing facility to produce injectable drug and distributes to over 18 countries worldwide.
Mission
Our mission is to improve the lives of those affected by renal disease by providing innovative and unique therapies that prevent, treat, and cure the complications of kidney disease and that are essential for optimal dialysis health.
Vision
Our vision is to drive growth through increased product awareness and utilization, a larger and more presence in major markets, and innovative solutions to improve the lives of those impacted by Renal Disease.
Key Team
Mr. James A. McCarthy (Sr. VP of Bus. & Corp. Devel.)
Mr. Timothy T. Chole (Sr. VP of Sales & Marketing)
Dr. Marc L. Hoffman M.D. (Sr. VP & Chief Medical Officer)
Ms. Heather R. Hunter (Sr. VP & Chief Corp. Affairs Officer)
Mr. Jason Finkelstein (Investor Relations Representative)
Mr. David J. Kull (Sec.)
Recognition and Awards
Rockwell Medical has been recognized in the 2017 Global Water Awards, ABILITY Magazine’s 2017 Healthcare Access Awards, as well as being a 2017 Top Workplace by the Detroit Free Press.
References